
[CLAIMS]

[Claim 1]

A compound represented by Chemical Formula 1 below, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof:

[Chemical Formula 1]



(In Chemical Formula 1,

X_1, X3 and X_4 are C, and X_2 is N or C;

Y is N, S, or O;

R_1 is a 6-membered cyclic aromatic group, 6-membered heterocyclic aromatic group, -CH_2-aryl, -CH_2-heteroaryl, a 6-membered cycloalkyl, a 6-membered heterocycloalkyl, -CO-aryl, or -CO-(C_4-C_5 alkyl), wherein the 6-membered heterocyclic

aromatic group includes one or more N atoms, and the 6-membered heterocycloalkyl includes one O atom, and

at least one H of R_1 is substituted with halogen, or a cyano group;

when all of X_1 to X_4 are C, R_2 is hydrogen or halogen, and when X_2 is N, R_2 is unsubstituted;

R_3 and R_4 are linked to each other to form a 5- or 6-membered heterocycloalkyl, wherein the 5- or 6-membered heterocycloalkyl includes one or two N atoms in the ring, and

at least one H in the 5- or 6-membered heterocycloalkyl formed by R_3 and R_4 is substituted with -OH, $-NH_2$, dimethylamine, -NH-(C_1-C_5 alkyl), $-NH-COCH_3$, $-NH-SO_2CH_3$, C_1-C_5 alkyl, or C_1-C_5 alkoxy;

when R_3 and R_4 do not form a ring, R_4 is hydrogen, and R_3 is C_2-C_{10} heterocycloalkyl, $-CH_2$-(C_3-C_6 cycloalkyl), $-CH_2$-(C_2-C_6 heterocycloalkyl), or $-CH_2$-(3- to 6-membered heterocyclic aromatic group), at least one H of R_3 is substituted with C_1-C_5 alkyl, acetyl, $-COCF_3$, or $-SO_2CH_3$; and

the heterocycloalkyl, heterocyclic group, and heteroaryl each independently include one or more hetero atoms selected from the group consisting of N, O, and S.)

.

[Claim 2]

The compound of claim 1, wherein the compound represented by Chemical Formula 1 is any one selected from the group consisting of the following compounds:

(1) (*R*)-6-fluoro-4-(4-fluorophenyl)-*N*-(pyrrolidin-3-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(2) (*R*)-6-fluoro-4-(4-fluorophenyl)-*N*-(1-methylpyrrolidin-3-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(3) (*R*)-6-fluoro-4-(4-fluorophenyl)-*N*-(1-isopropylpyrrolidin-3-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(4) (*R*)-6-fluoro-4-(4-fluorophenyl)-*N*-(1-isobutylpyrrolidin-3-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(5) (*R*)-6-fluoro-4-(4-fluorophenyl)-*N*-(1-(2,2,2-trifluoroacetyl)pyrrolidin-3-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(6) (*R*)-*N*-(1-acetylpyrrolidin-3-yl)-6-fluoro-4-(4-fluorophenyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(7) (*R*)-6-fluoro-4-(4-fluorophenyl)-*N*-(1-(methylsulfonyl)pyrrolidin-3-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(8) (*S*)-6-fluoro-4-(4-fluorophenyl)-*N*-(pyrrolidin-3-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(9) (*S*)-6-fluoro-4-(4-fluorophenyl)-*N*-(1-methylpyrrolidin-3-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(10) (*S*)-6-fluoro-4-(4-fluorophenyl)-*N*-(1-isopropylpyrrolidin-3-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(11) (*S*)-(3-aminopyrrolidin-1-yl)(6-fluoro-4-(4-fluorophenyl)-3,4-dihydroquinoxalin-1(2H)-yl)methanone;

(12) (*S*)-(6-fluoro-4-(4-fluorophenyl)-3,4-dihydroquinoxalin-1(2H)-yl)(3-(methylamino)pyrrolidin-1-yl)methanone;

(13) (*S*)-(6-fluoro-4-(4-fluorophenyl)-3,4-dihydroquinoxalin-1(2H)-yl)(3-(isobutylamino)pyrrolidin-1-yl)methanone;

(14) (*S*)-(6-fluoro-4-(4-fluorophenyl)-3,4-dihydroquinoxalin-1(2H)-yl)(3-(isopropylamino)pyrrolidin-1-yl)methanone;

(15) (*S*)-*N*-(1-(6-fluoro-4-(4-fluorophenyl)-1,2,3,4-tetrahydroquinoxaline-1-carbonyl)pyrrolidin-3-yl)acetamide;

(16) (*S*)-*N*-(1-(6-fluoro-4-(4-fluorophenyl)-1,2,3,4-tetrahydroquinoxaline-1-carbonyl)pyrrolidin-3-yl)methanesulfonamide;

(17) (*S*)-6-fluoro-4-(4-fluorophenyl)-*N*-(pyrrolidin-3-ylmethyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(18) (*R*)-6-fluoro-4-(4-fluorophenyl)-*N*-((1-methylpyrrolidin-3-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(19) (*R*)-6-fluoro-4-(4-fluorophenyl)-*N*-((1-isopropylpyrrolidin-3-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(20) (*R*)-6-fluoro-4-(4-fluorophenyl)-*N*-((1-isobutylpyrrolidin-3-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(21) (*R*)-6-fluoro-4-(4-fluorophenyl)-*N*-(pyrrolidin-2-ylmethyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(22) (*R*)-6-fluoro-4-(4-fluorophenyl)-*N*-((1-methylpyrrolidin-2-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(23) (*R*)-6-fluoro-4-(4-fluorophenyl)-*N*-((1-isopropylpyrrolidin-2-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(24) (*R*)-6-fluoro-4-(4-fluorophenyl)-*N*-((1-isobutylpyrrolidin-2-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(25) (*S*)-6-fluoro-4-(4-fluorophenyl)-*N*-((1-methylpyrrolidin-3-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(26) (*S*)-6-fluoro-4-(4-fluorophenyl)-*N*-((1-isopropylpyrrolidin-3-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(27) (*S*)-6-fluoro-4-(4-fluorophenyl)-*N*-((1-isobutylpyrrolidin-3-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(28) *N*-(cyclopropylmethyl)-6-fluoro-4-(4-fluorophenyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(29) 6-fluoro-4-(4-fluorophenyl)-*N*-(piperidin-4-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(30) 6-fluoro-4-(4-fluorophenyl)-*N*-(1-methylpiperidin-4-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(31) 6-fluoro-4-(4-fluorophenyl)-*N*-(1-isopropylpiperidin-4-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(32) 6-fluoro-4-(4-fluorophenyl)-*N*-(1-isobutylpiperidin-4-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(33) 6-fluoro-4-(4-fluorophenyl)-*N*-(piperidin-4-ylmethyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(34) 6-fluoro-4-(4-fluorophenyl)-*N*-(methylpiperidin-4-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(35) 6-fluoro-4-(4-fluorophenyl)-*N*-((1-isobutylpiperidin-4-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(36) 6-fluoro-4-(4-fluorophenyl)-*N*-((1-isopropylpiperidin-4-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(37) *N*-((1H-imidazol-4-)methyl)-6-fluoro-4-(4-fluorophenyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(38) 6-fluoro-4-(4-fluorophenyl)-*N*-(pyrazin-2-ylmethyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(39) (*R*)-(6-fluoro-4-(4-fluorophenyl)-3,4-dihydroquinoxalin-1(2H)-yl)(3-hydroxypyrrolidin-1-yl)methanone;

(40) (6-fluoro-4-(4-fluorophenyl)-3,4-dihydroquinoxalin-1(2H)-yl)(3-methoxypyrrolidin-1-yl)methanone;

(41) *N*-(azetidin-3-yl)-6-fluoro-4-(4-fluorophenyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(42) 6-fluoro-4-(4-fluorophenyl)-*N*-(1-isopropylazetidin-3-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(43) 6-fluoro-4-(4-fluorophenyl)-*N*-(1-isobutylazetidin-3-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(44) *N*-(1-acetylazetidin-3-yl)-6-fluoro-4-(4-fluorophenyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(45) 6-fluoro-4-(4-fluorophenyl)-*N*-((1-methylazetidin-3-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(46) 6-fluoro-4-(4-fluorophenyl)-*N*-((1-isopropylazetidin-3-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(47) 6-fluoro-4-(4-fluorophenyl)-*N*-((1-isobutylazetidin-3-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(48) 6-fluoro-4-(4-fluorophenyl)-*N*-((tetrahydrofuran-3-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(49) (*S*)-4-(4-fluorophenyl)-*N*-(pyrrolidin-3-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(50) 4-(4-fluorophenyl)-*N*-(piperidin-4-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(51) (*S*)-4-(4-fluorophenyl)-*N*-(tetrahydrofuran-3-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(52) 4-(4-fluorophenyl)-*N*-((tetrahydro-2H-pyran-4-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(53) (*S*)-4-(4-fluorophenyl)-*N*-(pyrrolidin-3-ylmethyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(54) (*R*)-4-(4-fluorophenyl)-*N*-((1-methylpyrrolidin-3-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(55) (*R*)-4-(4-fluorophenyl)-*N*-((1-isopropylpyrrolidin-3-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(56) (*R*)-4-(4-fluorophenyl)-*N*-((1-isobutylpyrrolidin-3-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(57) (*R*)-4-(4-fluorophenyl)-*N*-(pyrrolidin-2-ylmethyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(58) (*S*)-4-(4-fluorophenyl)-*N*-((1-methylpyrrolidin-3-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(59) (*S*)-4-(4-fluorophenyl)-*N*-((1-isopropylpyrrolidin-3-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(60) (*S*)-4-(4-fluorophenyl)-*N*-((1-isobutylpyrrolidin-3-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(61) 4-(4-fluorophenyl)-*N*-((1-isobutylazetidin-3-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(62) 4-(4-fluorophenyl)-*N*-(piperidin-4-ylmethyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(63) 4-(4-fluorophenyl)-*N*-((1-isopropylpiperidin-4-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(64) 4-(4-fluorophenyl)-*N*-((1-isobutylpiperidin-4-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(65) (*R*)-6-fluoro-4-phenyl-*N*-(pyrrolidin-3-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(66) (4-(2-chlorophenyl)-3,4-dihydroquinoxalin-1(2H)-yl)(piperidin-1-yl)methanone;

(67) 4-(2-chlorophenyl)-3,4-dihydroquinoxalin-1(2H)-yl)(pyrrolidin-1-yl)methanone;

(68) (4-(2-chlorophenyl)-3,4-dihydroquinoxalin-1(2H)-yl)(4-methylpiperazin-1-yl)methanone;

(69) (*S*)-*N*-(1-isopropylpyrrolidin-3-yl)-4-(pyridin-2-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(70) (*R*)-*N*-(1-acetylpyrrolidin-3-yl)-4-(pyridin-2-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(71) (*S*)-4-(pyridin-2-yl)-*N*-(pyrrolidin-3-ylmethyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(72) (*R*)-4-(pyridin-2-yl)-*N*-(pyrrolidin-2-ylmethyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(73) (*R*)-4-(pyridin-3-yl)-*N*-(tetrahydrofuran-3-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(74) *N*-(cyclopropylmethyl)-4-(pyridin-4-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(75) (*R*)-4-(5-fluoropyridin-2-yl)-*N*-(1-methylpyrrolidin-3-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(76) (*R*)-4-(5-fluoropyridin-2-yl)-*N*-(1-methylpyrrolidin-3-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(77) 4-(5-fluoropyridin-2-yl)-*N*-(1-methylpiperidin-4-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(78) (*S*)-(3-aminopyrrolidin-1-yl)(4-(5-fluoropyridin-2-yl)-3,4-dihydroquinoxaline-1(2H)-methanone;

(79) (*S*)-4-(4-cyanophenyl)-*N*-(pyrrolidin-3-ylmethyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(80) (*S*)-4-(pyrazin-2-yl)-*N*-(pyrrolidin-3-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(81) (*S*)-*N*-(1-isopropylpyrrolidin-3-yl)-4-(pyrazin-2-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(82) *N*-(1-isobutylpiperidin-4-yl)-4-(pyrazin-2-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(83) *N*-(1-isopropylpiperidin-4-yl)-4-(pyrazin-2-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(84) (*R*)-4-benzyl-*N*-(pyrrolidin-3-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(85) (*S*)-(3-aminopyrrolidin-1-yl)(4-benzyl-3,4-dihydroquinoxalin-1(2H)-yl)methanone;

(86) (*S*)-(4-benzyl-3,4-dihydroquinoxalin-1(2H)-yl)(3-(methylamino)pyrrolidin-1-yl)methanone;

(87) (*R*)-4-(2-fluorobenzyl)-*N*-(1-methylpyrrolidin-3-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(88) 4-(2-fluorobenzyl)-*N*-(1-methylpiperidin-4-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(89) 4-(2-fluorobenzyl)-*N*-((1-methylpiperidin-4-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(90) (*R*)-4-(2-fluorobenzyl)-*N*-((1-methylpyrrolidin-3-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(91) (*R*)-4-(4-fluorobenzyl)-*N*-(pyrrolidin-3-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(92) (*R*)-4-(4-fluorobenzyl)-*N*-(1-isopropylpyrrolidin-3-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(93) 4-(4-fluorobenzyl)-*N*-(piperidin-4-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(94) 4-(4-fluorobenzyl)-*N*-(1-isopropylpiperidin-4-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(95) (*R*)-4-(4-chlorobenzyl)-*N*-(pyrrolidin-3-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(96) (*S*)-(3-(isobutylamino)pyrrolidin-1-yl)(4-(pyridin-2-ylmethyl)-3,4-dihydroquinoxalin-1(2H)-yl)methanone;

(97) (S)-(3-(dimethylamino)pyrrolidin-1-yl)(4-(pyridin-2-ylmethyl)-3,4-dihydroquinoxalin-1(2H)-yl)methanone;

(98) (*R*)-4-(pyridin-2-ylmethyl)-*N*-(tetrahydrofuran-3-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(99) *N*-(oxetan-3-yl)-4-(pyridin-2-ylmethyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(100) 4-(pyridin-2-ylmethyl)-*N*-((tetrahydrofuran-3-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(101) 4-(pyridin-2-ylmethyl)-*N*-((tetrahydro-2H-pyran-4-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(102) *N*-(cyclopropylmethyl)-4-(pyridin-2-ylmethyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(103) (4-(4-fluorophenyl)-3,4-dihydropyrido[3,4-*b*]pyrazin-1(2H)-yl)(3-hydroxypyrrolidin-1-yl)methanone;

(104) (*R*)-4-cyclohexyl-*N*-(pyrrolidin-3-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(105) (*R*)-4-cyclohexyl-*N*-(1-methylpyrrolidin-3-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(106) (*R*)-4-cyclohexyl-*N*-(1-isobutylpyrrolidin-3-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(107) (4-cyclohexyl-3,4-dihydroquinoxalin-1(2H)-yl)(4-methylpiperazin-1-yl)methanone;

(108) (4-cyclohexyl-3,4-dihydroquinoxalin-1(2H)-yl)(pyrrolidin-1-yl)methanone;

(109) (4-cyclohexyl-3,4-dihydroquinoxalin-1(2H)-yl)(piperidin-1-yl)methanone;

(110) (*R*)-*N*-(1-methylpyrrolidin-3-yl)-4-(tetrahydro-2H-pyran-4-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(111) (*R*)-*N*-(1-isobutylpyrrolidin-3-yl)-4-(tetrahydro-2H-pyran-4-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(112) (*S*)-(3-aminopyrrolidin-1-yl)(4-(tetrahydro-2H-pyran-4-yl)-3,4-dihydroquinoxalin-1(2H)-yl)methanone;

(113) (*S*)-(3-(dimethylamino)pyrrolidin-1-yl)(4-(tetrahydro-2H-pyran-4-yl)-3,4-dihydroquinoxalin-1(2H)-yl)methanone;

(114) 4-benzoyl-*N*-(piperidin-4-ylmethyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(115) (*S*)-4-benzoyl-*N*-(pyrrolidin-3-ylmethyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(116) (*R*)-4-benzoyl-*N*-((1-methylpyrrolidin-3-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(117) (*S*)-4-(2-fluorobenzoyl)-*N*-(pyrrolidin-3-ylmethyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(118) (*R*)-4-(2-fluorobenzoyl)-*N*-((1-methylpyrrolidin-3-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(119) (*R*)-4-(3-fluorobenzoyl)-*N*-(pyrrolidin-3-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(120) (*S*)-4-(3-fluorobenzoyl)-*N*-(pyrrolidin-3-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(121) (*R*)-4-(3-fluorobenzoyl)-*N*-((1-methylpyrrolidin-3-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(122) (*S*)-4-(4-fluorobenzoyl)-*N*-(pyrrolidin-3-ylmethyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(123) (*R*)-4-(4-fluorobenzoyl)-*N*-((1-methylpyrrolidin-3-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(124) 4-(4-fluorobenzoyl-*N*-(piperidin-4-yl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(125) 4-(3-methylbutanoyl)-*N*-(piperidin-4-ylmethyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(126) 4-(3-methylbutanoyl)-*N*-((1-methylpiperidin-4-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(127) *N*-((1-isobutylpiperidin-4-yl)methyl)-4-(3-methylbutanoyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(128) (*R*)-4-(3-methylbutanoyl)-*N*-((1-methylpyrrolidin-3-yl)methyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide;

(129) (*R*)-4-(3,3-dimethylbutanoyl)-*N*-(pyrrolidin-3-ylmethyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide; and

(130) 4-(3,3-dimethylbutanoyl)-*N*-(piperidin-4-ylmethyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide.

[Claim 3]

A pharmaceutical composition for preventing or treating a pulmonary fibrosis-related disease, comprising the compound represented by Chemical Formula 1 of claim 1, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.

[Claim 4]

The pharmaceutical composition of claim 3, wherein the composition inhibits actin polymerization.

[Claim 5]

The pharmaceutical composition of claim 3, wherein the composition inhibits the level or activity of an inflammatory cytokine.

[Claim 6]

The pharmaceutical composition of claim 3, wherein the composition reduces the level or activity of one or more proteins selected from the group consisting of α-SMA, F-actin, and IL-6.

[Claim 7]

The pharmaceutical composition of claim 3, wherein the pulmonary fibrosis-related disease is one or more selected from the group consisting of pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), desquamative interstitial pneumonia, non-specific interstitial pneumonia, cryptogenic organizing pneumonia, respiratory bronchiolitis-associated interstitial lung disease, acute interstitial pneumonia, lymphocytic interstitial pneumonia, idiopathic pleuroparenchymal fibroelastosis, and chronic obstructive pulmonary disease (COPD).

[Claim 8]

The pharmaceutical composition of claim 3, wherein the pulmonary fibrosis-related disease is a pulmonary fibrosis-related disease accompanied by the overactivation of actin polymerization.

[Claim 9]

A kit for preventing or treating a pulmonary fibrosis-related disease, comprising the composition of any one of claims 3 to 8.